Aptamer-Immunotherapy Platform
Oncology
Pre-clinicalActive
Key Facts
About Bioptamers
Founded in 2016, Bioptamers is a private, pre-revenue biotech focused on revolutionizing cancer treatment through personalized, aptamer-based drug delivery. The company's core technology is a microfluidic platform for selecting synthetic molecules (aptamers) that can precisely deliver chemical, radiation, or immunological therapies directly to tumors. While still in the pre-clinical development stage, Bioptamers aims to address the significant global oncology market by improving therapeutic outcomes and reducing off-target effects. Its strategy involves academic and industry collaborations to translate its platform into clinical candidates.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |